Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
REC-01
- Development stage
- Unknown
- Lead developer
- PuREC
- Modality
- Stem Cell Therapies → Cell Therapies
- Administration
- Intravenous
01
Overview
REC-01 is a high-purity mesenchymal stem cell (MSC) product derived from donor bone marrow, developed by PuREC Co., Ltd. using its proprietary cell selection technology. It is specifically designed for the treatment of severe pediatric hypophosphatasia (HPP), a rare genetic disorder characterized by defective bone mineralization due to a deficiency in tissue-nonspecific alkaline phosphatase (TNSALP). REC-01 is intended to be administered alongside umbilical cord blood transplantation (UCBT) to provide a sustainable source of alkaline phosphatase-producing cells. The product is currently being evaluated in a Phase I/IIa clinical trial in Japan for patients who are already receiving asfotase alfa but require additional therapeutic support.
- Other names
- high-purity mesenchymal stem cells
Beyond the preview
Go deeper on REC-01.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on REC-01.